Stock NVCR NOVOCURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
20.32 USD +13.01% Intraday chart for NovoCure Limited +30.84% +36.10%
May. 02 NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue MT
May. 02 BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue
MT
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg
MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure
AN
Transcript : NovoCure Limited, Q1 2024 Earnings Call, May 02, 2024
NovoCure: Q1 Earnings Snapshot
AQ
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M
MT
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
BU
Novocure Reports First Quarter 2024 Financial Results
BU
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Novocure Enters into New Five-Year Up to $400 Million Committed Senior Secured Credit Facility with Funds Managed by Pharmakon Advisors, LP
CI
NovoCure Limited announced that it expects to receive $400 million in funding
CI
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
BU
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer
CI
NovoCure : Corporate responsibility report
PU
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating
MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024
AQ
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer
MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
BU
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating
MT
Novocure to Report First Quarter 2024 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVCR Stock
  4. News NovoCure Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW